COVID-19 vaccines are already authorized for children ages 12 and older, and the shots now have the support of a U.S. Food and Drug Administration (FDA) expert panel for younger children ages 5 to 11.
In a 17 to 0 vote, with one abstention, the committee recommended the COVID-19 vaccine made by Pfizer-BioNTech for the youngest group yet to potentially get immunized against the disease in the U.S. The committee recommended a two-dose regimen at one-third the dosage approved for adults.
The FDA now takes the committee's advice into consideration before making a final recommendation. If the agency decides to recommend the vaccine, the Centers for Disease Control and Prevention (CDC) will then detail which specific groups of children in that age range should get vaccinated. (For example, after weighing the benefits of risks, the agency's public health experts could recommend only children at high risk of severe COVID-19 get the shot.)
Please select this link to read the complete article from TIME.